LABU241220C147000
- 0.00
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Another Week, Another Index Record | Lkive Stock
PepGen Stock Craters 35% on FDA Clinical Hold
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target
Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494
Vertex Pharmaceuticals Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
Weekly Buzz: Tech stocks hit high scores on ominous day
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Market Mixed on Friday the 13th | Livestock
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Natera Analyst Ratings
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...
Thursday Ends in Index Declines | Wall Street Today
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites